Corrigendum: Alpha-fetoprotein measurement benefits hepatocellular carcinoma surveillance in patients with cirrhosis (American Journal of Gastroenterology (2015) 110 (836-844) DOI: 10.1038/ajg.2015.100);Alpha-fetoprotein measurement benefits hepatocellular carcinoma surveillance in patients with cirrhosis

American Journal of Gastroenterology

Volumn 110, Issue 6, 2015, Pages 836-844

  Chang, Te Sheng ^a,b,c   Wu, Yu Chih ^c   Tung, Shui Yi ^a,d   Wei, Kuo Liang ^a   Hsieh, Yung Yu ^a   Huang, Hao Chun ^a   Chen, Wei Ming ^a,b   Shen, Chien Heng ^a,b   Lu, Chang Hsien ^a,b   Wu, Cheng Shyong ^a,d   Tsai, Ying Huang ^a,d   Huang, Yen Hua ^c,e  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^d CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^e TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALPHA FETOPROTEIN; BILIRUBIN; TUMOR MARKER;

ADULT; AGE DISTRIBUTION; ALBUMIN BLOOD LEVEL; ARTICLE; BILIRUBIN BLOOD LEVEL; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CHILD PUGH SCORE; ECHOGRAPHY; FEMALE; FOLLOW UP; HEPATITIS B; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; THROMBOCYTE COUNT; AGED; CARCINOMA, HEPATOCELLULAR; COMPLICATION; EARLY DIAGNOSIS; LIVER; LIVER NEOPLASMS; METABOLISM; MIDDLE AGED; PROCEDURES;

AGED; ALPHA-FETOPROTEINS; CARCINOMA, HEPATOCELLULAR; EARLY DETECTION OF CANCER; FEMALE; HUMANS; LIVER; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; ROC CURVE; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 84930758143     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2016.426     Document Type: Erratum

References (28)

1. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007;132: 2557-76.
2. Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol 2009;27: 1485-91.
3. Llovet JM, Bustamante J, Castells A et al. Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology 1999;29: 62-7.
4. Llovet JM, Bruix J. Early diagnosis and treatment of hepatocellular carcinoma. Baillieres Best Pract Res Clin Gastroenterol 2000;14: 991-1008.
5. Ioannou GN, Perkins JD, Carithers RL Jr. Liver transplantation for hepatocellular carcinoma: impact of the MELD allocation system and predictors of survival. Gastroenterology 2008;134: 1342-51.
6. Stravitz RT, Heuman DM, Chand N et al. Surveillance for hepatocellular carcinoma in patients with cirrhosis improves outcome. Am J Med 2008;121: 119-26.
7. European Association for the Study of the Liver: European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012;56: 908-43.
8. Bruix J, Sherman M. American Association for the Study of Liver Diseases: management of hepatocellular carcinoma: an update. Hepatology 2011;53: 1020-2.
9. Omata M, Lesmana LA, Tateishi R et al. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int 2010;4: 439-74.
10. Kudo M, Izumi N, Kokudo N et al. HCC Expert Panel of Japan Society of Hepatology: management of hepatocellular carcinoma in Japan: consensusbased clinical practice guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version. Dig Dis 2011;29: 339-64.
11. Lok AS, Sterling RK, Everhart JE et al. HALT-C trial group. des-gammacarboxy prothrombin and alpha fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology 2010;138: 493-502.
12. Forner A, Reig M, Bruix J. ?-fetoprotein for hepatocellular carcinoma diagnosis: the demise of a brilliant star. Gastroenterology 2009;137: 26-9.
13. Sherman M. Serological surveillance for hepatocellular carcinoma: time to quit. J Hepatol 2011;52: 614-5.
14. Singal AG, Volk ML, Waljee A et al. Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther 2009;30: 37-47
15. Chang YC, Nagasue N, Abe S et al. Alpha fetoprotein producing early gastric cancer with liver metastasis: report of three cases. Gut 1991;32: 542-5.
16. Lin YC, Lee PH, Yao YT et al. Alpha-fetoprotein producing pancreatic acinar cell carcinoma. J Formos Med Assoc 2007;106: 669-72.
17. Ishikawa K, Sasaki A, Haraguchi N et al. A case of an alpha-fetoproteinproducing intrahepatic cholangiocarcinoma suggests probable cancer stem cell origin. Oncologist 2007;12: 320-4.
18. Lok AS, Lai CL. Fetoprotein monitoring in Chinese patients with chronic hepatitis B virus infection: role in the early detection of hepatocellular carcinoma. Hepatology 1989;9: 110-5.
19. Liaw YF, Tai DI, Chen TJ et al. Alpha-fetoprotein changes in the course of chronic hepatitis: relation to bridging hepatic necrosis and hepatocellular carcinoma. Liver 1986;6: 133-7.
20. Oka H, Tamori A, Kuroki T et al. Prospective study of alpha-fetoprotein in cirrhotic patients monitored for development of hepatocellular carcinoma. Hepatology 1994;19: 61-6.
21. Singal AG, Conjeevaram HS, Volk ML et al. Effectiveness of hepato cellular carcinoma surveillance in patients with cirrhosis. Cancer Epidemiol Biomarkers Prev 2012;21: 793-9.
22. Marrero JA, El-Serag HB. Alpha-fetoprotein should be included in the hepatocellular carcinoma surveillance guidelines of the American Association for the Study of Liver Diseases. Hepatology 2011;53: 1060-1.
23. Lederle FA, Pota C. Screening for hepatocellular carcinoma: a rush to judgment. Ann Int Med 2012;156: 387-9.
24. Ciolli A, Fraquelli M, Casazza G et al. Accuracy of ultrasonography, spiral CT, magnetic resonance, and alpha-fetoprotein in diagnosing hepatocellular carcinoma: a systematic review. Am J Gastroenterol 2006;101: 513-23.
25. Marrero JA, Feng Z, Wang Y et al. Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology 2009;137: 110-8.
26. Lee E, Edward S, Singal AG et al. Improving screening for hepatocellular carcinoma by incorporating data on levels of Fetoprotein, over time. Clin Gastroenterol Hepatol 2013;11: 437-40.
27. Jepsen P, Ott P, Andersen PK et al. Risk for hepatocellular carcinoma in patients with alcoholic cirrhosis: a Danish nationwide cohort study. Ann Intern Med 2012;156: 841-7.
28. Lee CM, Lu SN, Changchien CS et al. Age, gender, and local geographic variations of viral etiology of hepatocellular carcinoma in a hyperendemic area for hepatitis B virus infection. Cancer 1999;186: 1143-50.